Paper
0
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Authors
Barton Haynes,Peter Gilbert
M. McElrath,Susan Zolla‐Pazner,Georgia Tomaras,S. Alam,David Evans,David Montefiori,Chitraporn Karnasuta,Reungpung Sutthent,Hua-Xin Liao,Anthony DeVico,George Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin Robb,Viseth Ngauy,Mark Souza,Robert Paris,Guido Ferrari,Robert Bailer,Kelly Soderberg,Charla Andrews,Phillip Berman,Nicole Frahm,Stephen Rosa,Michael Alpert,Nicole Yates,Xiaoying Shen,Richard Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Nelson Michael,Jerome Kim,Supachai Rerks‐Ngarm
+41 authors
,Ruengpueng SutthentPublished
Apr 4, 2012
Show more
Save
Tip0
TipSave
Abstract
In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to identify antibody and cellular immune correlates of infection risk.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.